# ITIL-306

Source: https://onco.cc/drugs/itil-306/  
OnCo record `itil-306` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ITIL-306 is an autologous tumour-infiltrating lymphocyte cell therapy with a co-stimulatory antigen receptor from Instil Bio that reached phase 1 for epithelial ovarian cancer, non-small cell lung cancer and renal cell carcinoma; development has stopped.

## Summary

ITIL-306 (CoStAR-TIL) is an autologous tumour-infiltrating lymphocyte (TIL) cell therapy with a co-stimulatory antigen receptor (CoStAR) from Instil Bio. A cell therapy made from the patient's own tumour-infiltrating lymphocytes that carries a molecule designed to increase TIL activity when it meets folate receptor alpha (FOLR1) on the tumour. Its furthest stage is phase 1, for epithelial ovarian cancer, non-small cell lung cancer and renal cell carcinoma. ClinicalTrials.gov registers it in one study linked below. Form 10-K for 2025 says the ITIL-306 trials were discontinued; NCT05397093 TERMINATED. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: CoStAR-TIL
- Tags: pipeline; ctgov-ingest; discontinued
- Code: ITIL-306
- Modality: Autologous tumour-infiltrating lymphocyte (TIL) cell therapy with a co-stimulatory antigen receptor (CoStAR)
- Mechanism: A cell therapy made from the patient's own tumour-infiltrating lymphocytes that carries a molecule designed to increase TIL activity when it meets folate receptor alpha (FOLR1) on the tumour.

## Sources

- Instil Bio: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05397093
- Instil Bio: sec.gov: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000019/til-20251231.htm
- Instil Bio: sec.gov: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000019/til-20251231.htm
- ClinicalTrials.gov: trials of ITIL-306: https://clinicaltrials.gov/search?intr=ITIL-306

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- targets: [Folate receptor alpha](https://onco.cc/targets/folr1/)
- companies: [Instil Bio](https://onco.cc/companies/instil-bio/)
- trials: [ITIL-306 in Advanced Solid Tumors](https://onco.cc/trials/nct05397093/)

---
JSON: https://onco.cc/api/v1/entities/itil-306.json